These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25932758)

  • 1. Walking a tightrope: targeting neutrophils to treat chronic obstructive pulmonary disease.
    Aaron SD
    Am J Respir Crit Care Med; 2015 May; 191(9):971-2. PubMed ID: 25932758
    [No Abstract]   [Full Text] [Related]  

  • 2. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebuttal from Drs Suissa and Rabe.
    Suissa S; Rabe KF
    Chest; 2014 May; 145(5):942-3. PubMed ID: 24798832
    [No Abstract]   [Full Text] [Related]  

  • 4. Point: were industry-sponsored roflumilast trials appropriate? Yes.
    Suissa S; Rabe KF
    Chest; 2014 May; 145(5):937-9. PubMed ID: 24798830
    [No Abstract]   [Full Text] [Related]  

  • 5. A new two-step algorithm for the treatment of COPD.
    Miravitlles M; Anzueto A
    Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28179443
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutrophils in chronic inflammatory airway diseases: can we target them and how?
    Gernez Y; Tirouvanziam R; Chanez P
    Eur Respir J; 2010 Mar; 35(3):467-9. PubMed ID: 20190324
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
    J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel drugs for COPD treatment].
    Gillissen A
    MMW Fortschr Med; 2014 Aug; 156(14):68-9, 71. PubMed ID: 25195414
    [No Abstract]   [Full Text] [Related]  

  • 9. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.
    Hastrup N; Khalilieh S; Dale DC; Hanson LG; Magnusson P; Tzontcheva A; Tseng J; Huyck S; Rosenberg E; Krogsgaard K
    Cytokine; 2015 Apr; 72(2):197-203. PubMed ID: 25661195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroids and chronic obstructive pulmonary disease in the nursing home.
    Rich A
    J Am Med Dir Assoc; 2005; 6(3 Suppl):S68-74. PubMed ID: 15890302
    [No Abstract]   [Full Text] [Related]  

  • 12. Does roflumilast induce phagocytic activity in COPD patients?
    Ghosh B; Vanjare NV
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1931-4. PubMed ID: 26392768
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils.
    Pedersen F; Waschki B; Marwitz S; Goldmann T; Kirsten A; Malmgren A; Rabe KF; Uddin M; Watz H
    Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29449427
    [No Abstract]   [Full Text] [Related]  

  • 14. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple inhalers for obstructive airways disease: will they be useful?
    Barnes PJ
    Expert Rev Respir Med; 2011 Jun; 5(3):297-300. PubMed ID: 21702649
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel combined candidate--new hopes for COPD maintenance therapy!?
    Mihălţan F; Ulmeanu R
    Pneumologia; 2015; 64(3):9-11. PubMed ID: 26740985
    [No Abstract]   [Full Text] [Related]  

  • 17. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
    Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
    Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the advances in chronic obstructive pulmonary disease treatment.
    Metzger NL; Lundquist LM
    J Pharm Pract; 2012 Dec; 25(6):576-82. PubMed ID: 23076966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov; 145(46):47. PubMed ID: 14699834
    [No Abstract]   [Full Text] [Related]  

  • 20. New therapies for chronic obstructive pulmonary disease.
    Barnes PJ
    Med Princ Pract; 2010; 19(5):330-8. PubMed ID: 20639653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.